SDI FINAL EVALUATION FORM 1.1

PART 1:

Journal Name:	**Journal of Cancer and Tumor International**
Manuscript Number:	**Ms_JCTI_20417**
Title of the Manuscript:	**Prognostic Value of KRAS Mutations in Patients with Colorectal Cancer: South Egypt Cancer Institute Experience**
Type of the Article	**Original Research Article**

PART 2:	
FINAL EVALUATOR'S comments on revised paper (if any)	**Authors' response to final evaluator's comments**
Thank you for the corrections, but it is necessary to edit the text, because there are some grammatical and stylistic errors **(see first review).** The manuscript was not corrected by a professional editor.	-The text has been edited.
If you use the title "Prognostic Value of *KRAS* Mutations in Codons 12 and 13 in South Egyptian Colorectal Cancer Patients", you should add "Acknowledgements" and include the South Egypt Cancer Institute and/or something/somebody else.	-Acknowledgements have been added.
It necessary to change ":Results .3" to "3. Results:"	-Has been corrected.
It necessary to change "The age ranged from 34 to 68 years (**T**he mean age: 50.8 years ± 11.0)." to "The age ranged from 34 to 68 years (**t**he mean age: 50.8 years ± 11.0)."	-Has been corrected.
Table 1 It necessary to delete "%" for each result excepting the the title of column (No. of mutations (%) out of 25 cases).	-Has been deleted.
Table 1 It necessary to change "No. of mutations (%) **O**ut of 25 cases" to "No. of mutations (%) **o**ut of 25 cases".	-Has been changed.
Footnotes should be placed below the table with superscript lowercase letters(see Author's Instruction).	-Footnotes have been placed below the tables.
Table 2-3 It necessary to delete "%" for each result excepting the the title of 2 columns.	-Percentages have been deleted.
Figure 3-6 Each figure should have a caption. The caption should be concise and typed separately, not on the figure area (see Author's Instruction).**(see first review)** The captions have not deleted from figures area.	-Figure caption has been placed outside the figure area.
Abbreviations have not revised **(see first review)**.: Non-standard abbreviations should be listed and full form of each abbreviation should be given in parentheses at first use in the text(see Author's Instruction): "2.3 Statistical method: **Overall survival (OS)** was defined as the interval from enrollment to the date of death	-Abbreviations have been revised.

from any cause or last follow up."; The title of axis (Figure 3, 5) "% **Overall survival (OS)**".	-Has been changed to OS, %.
1. Introduction: "… a phase III randomized trial of patients with stage III colon cancer demonstrated the prognostic value of *KRAS* mutation status (3-year **DFS**)…" (It was a first use, but there is not a full form).	-Has been written in full form.
2.3 Statistical method: "**Disease free survival (DFS)** was defined as the interval from enrollment of patients to the date of relapse or death from any cause or last follow up." The title of axis (Figure 3, 5) "% **Disease free survival (DFS)**".	-Has been changed to DFS, %.
"Furthermore, the CTRL reaction was used to display a normal **wild type (WT)** specific melting temperature as reference." **"WILD type (WT)** LOW reaction:"	-Has been corrected to Wild type (WT) LOW reaction.
"**Colorectal cancer (CRC)** is the fourth most common cancer in men and the third most common in women [1]. Approximately 40% of **colorectal cancers (CRCs)** harbor ..."; "This study included 79 previously untreated **colorectal cancer (CRC)**" "13 **C (Cystein)** LOW reaction: Sample must show a peak at about 56℃ 12 **C (Cystein)** HIGH reaction:"	-Have been corrected.
Guideline for Reporting *P* values: *P* is always italicized and capitalized. Correct expression: (*P* = .05)(see Author's Instruction). **(see first review)**. It was not capitalized and italicized: "...(83.1% vs 90.7%, p=0.04) ..."	-*P* has been capitalized and italicized.
It necessary to change the title of axis (Figure 4,6) "% Disease free survival (DFS)" to "DFS, %"	-Has been corrected.
It necessary to change the title of axis (Figure 3, 5) "% Overall survival (OS)" to "OS, % " .	-Has been corrected.
It necessary to change ""-ve" negative, "+ve" positive" to "The symbol "-ve" means negative value and the symbol "+ve" means positive value" or to another explication.	-Has been corrected.
"*KRAS*" gene must be in italic type **(see first review)**. It has not italicized in all places: "Kras status" in the Figure 3-4. "2.1.1 Surgery: … the margins were examined histopathologically and subjected to KRAS mutation analysis." "PCR amplifications: The assay was based on the PCR amplification of a fragment from exon/intron 1 of the human KRAS gene ..." *"2.2 Tissue handling* KRAS mutation detection" "Samples displayed a clear peak in the HIGH reaction contained a mutated KRAS gene." "Figure 2: KRAS mutation detection assay for 3 cases of colorectal cancer " "KRAS mutation detection assay for 3 cases of colorectal cancer revealed that each sample represented by 3 reactions..." "… patterns of failure and KRAS mutation status, ..." "… (25 out of 79) in KRAS gene." "Among 25 cases with KRAS mutated CRC, ..." "Table 1: Distribution of the 25 mutations of KRAS gene" Table 3 "KRAS mutation status" "However, Bazan et al, showed an association between the KRAS mutation..." "Wangefjord et al., reported similar survival for patients with KRAS wild-type and codon 12-mutated tumors, while patients with tumors harbouring a KRAS codon 13 mutation had	-KRAS has been italicized.

a significantly reduced Cancer specific survival (HR = 1.94; 95% CI = 1.18–3.19) in unadjusted, but not in adjusted analysis [18].” Why was “Cancer” capitalized? “Imamura et al., observed that specific *KRAS* mutations ...” “Andreyev et al., reported that the presence of a somatic KRAS mutation” “… while KRAS codon 12 mutations were not significantly associated with reduced DFS or OS.” You can use “gene name + gene” or *”gene name italicized”:* “Detection of mutations in the region codons 12 to 13 of the *KRAS* gene, in particular mutations 12D, 12C, 12V, 12A, 12R, 12S, 12T, 13D, 12D13D and 13C.” “Samples which contained significant amounts of mutated *KRAS* gene copies (>10-20%), ...” There are some errors: “...South Egypt Cancer Institute from January 2011 to June **2013and** all patients were evaluated ...” “in particular mutations 12D, 12C, 12V, 12A, 12R, 12S, 12T, 13D, **12D13D** and 13C.” “proliferation and differentiation signals [**4,5**]. ” “...some studies reported no association with survival [**7,8**],...” “therapy in metastatic setting [1**0,1**1].” “**Histologicallly** proven CRC” “Capcitabine was given concurrent with radical radiotherapy by a dose 825 mg/ m^2 **twice daily.** “ “South Egypt cancer **Instiute**” … etc.	-Errors have been corrected.
Figure 5: Why was the word “Codon” capitalized?	
2.2 Tissue handling It necessary to change “KRAS mutation detection” to “*KRAS* mutation detection.” .	-Has been corrected.
“The DNA yield vary from 15- 150 ng*/ul”* Where is the point? Why was“*ul”* italicized? Why was“*2.2 Tissue handling”* italicized? “2.1 Diagnosis and treatment:” was not italicized.	-Has been corrected to be, DNA concentration was defined with a range of 15- 150 ng/ul (the mean value of 70 ng/ul). Has been edited to be not italicized.
Why was different size of type used in the text of discussion?	-Font size has been corrected.
“CRC cases between 2000 and 2002 and found that the median age was 53 years (Range 21-81 years)...” Why was “Range” capitalized?	-Has been corrected to (range).
“...the presence of lymph node metastasis and high SPF...”. What is “SPF”?	-Has been written (S-phase fraction) in the text.
The abbreviations “ASRs”, “(ECOG)” and “(SECI)” was not used after the first mention. It is necessary to delete “(ASRs)”, “(ECOG)” and “(SECI)”: “age-standardized rates (ASRs)” in the discussion. “...South Egypt cancer Instiute (SECI)” in the discussion. “...Eastern Cooperative Oncology Group (ECOG) system” in Patients and Methods.	-The abbreviations have been deleted.
It necessary to change “6.Consent:”, “7. Ethical Approval:”, “8. Competing interest:”, “9. References:” to “Consent:”, “Ethical Approval:”, “Competing interest:”, “References:”	-Has been changed.
It necessary to change “Abstract:”, “1. Introduction:”, “2. Patients and Methods:”, “3. Results:”, “5. Conclusion:” to “Abstract”, “1. Introduction”, “2. Patients and Methods”, “3. Results”, “5. Conclusion”.	-Abstract has been changed to include: Aims, patients and methods, results and

All references should follow the following style **(see first review)**: 1. Hilly M, Adams ML, Nelson SC. A study of digit fusion in the mouse embryo. Clin Exp Allergy. 2002;32(4):489-98. (see Author's Instruction): “1.Siegel R, Naishadham D and Jemal A: Cancer statistic**s.C**A Cancer J Clin **Jan-Feb** 2012;62(1):10-29.” …. etc. Please, correct other similar errors.	conclusion -References have been revised.